Clinical Trials Browser

Has results × Dasatinib × Thoracic × Clear all

NCT02954523 2024-07-05

Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Phase 1/2 Terminated

10 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01999985 2020-11-27

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

25 enrolled 10 charts

Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Pleural Diseases, Pleural Effusion, Pleural Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Pleural Effusion, Malignant

NCT00459342 2019-03-05

Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Phase 2 Completed

35 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT00509041 2016-08-11

Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma

Phase 2 Completed

46 enrolled 14 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT00826449 2016-06-28

Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Completed

53 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00570401 2016-01-22

Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib

Phase 2 Completed

22 enrolled 6 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00470054 2015-05-05

Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer

Phase 2 Completed

44 enrolled 10 charts

Small Cell Lung Carcinoma

NCT00564876 2015-02-23

TOP0706

Phase 2 Terminated

2 enrolled 4 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT01491633 2014-07-15

Dasatinib in Advanced Squamous Cell Lung Cancer

Phase 2 Terminated

5 enrolled 7 charts

Lung Neoplasms

NCT00858403 2014-01-15

Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation

Phase 2 Terminated

7 enrolled 7 charts

Lung Neoplasms